ConductScience.org, home

Paper2909288

Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.

Dumas M and 6 others. Cancer Chemother Pharmacol, 1989. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum. Papers, record 2909288. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2909288

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1989
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
1.02
iCite
Revised in PubMed
2019-08-28
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dumas MM
2de Gislain CC
3d'Athis PP
4Chadoint-Noudeau VV
5Escousse AA
6Guerrin JJ
7Autissier NN

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CisplatinMajor topic
FurosemideMajor topic
PlatinumMajor topic
Humans
Kidney
Metabolic Clearance Rate
Ultrafiltration

Source PubMed

Download CSV of topics

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1498151Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).Cancer Treat Rep1979https://conductscience.org/library/papers/498151PubMed
2856437High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.Cancer1977https://conductscience.org/library/papers/856437PubMed
3118952The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity.Int J Radiat Oncol Biol Phys1979https://conductscience.org/library/papers/118952PubMed
43542269Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3542269PubMed
5421210Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats.Cancer Res1979https://conductscience.org/library/papers/421210PubMed
66685336Mechanisms of renal excretion of cisdichlorodiamine platinum.Res Commun Chem Pathol Pharmacol1983https://conductscience.org/library/papers/6685336PubMed
7844049Prevention of renal failure in rats receiving cis-diamminedichloroplatinum(II) by administration of furosemide.Cancer Res1977https://conductscience.org/library/papers/844049PubMed
86161715Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/6161715PubMed
96890406Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism.Cancer Treat Rep1982https://conductscience.org/library/papers/6890406PubMed
106537801Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6537801PubMed
114053272Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II).Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/4053272PubMed
126889863The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum ii) and its modification by furosemide and probenecid.Biochem Pharmacol1982https://conductscience.org/library/papers/6889863PubMed
134039530Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations.Am J Clin Oncol1985https://conductscience.org/library/papers/4039530PubMed
14159127Platinate toxicity: past, present, and prospects.Cancer Treat Rep1979https://conductscience.org/library/papers/159127PubMed
153891281Cisplatin nephrotoxicity: a summary of preventative interventions.Drug Intell Clin Pharm1985https://conductscience.org/library/papers/3891281PubMed
164044076Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II).Int J Clin Pharmacol Ther Toxicol1985https://conductscience.org/library/papers/4044076PubMed
17421230Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum(II) administered with hydration and mannitol diuresis.Cancer Treat Rep1979https://conductscience.org/library/papers/421230PubMed
186784924High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.Cancer Treat Rep1981https://conductscience.org/library/papers/6784924PubMed

Download CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
28856465Guidelines for treatment of renal injury during cancer chemotherapy 2016.Clin Exp Nephrol2018https://conductscience.org/library/papers/28856465PubMed
8281624Combination chemotherapy of human ovarian xenografts with intraperitoneal liposome-incorporated valinomycin and cis-diamminedichloroplatinum(II).Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8281624PubMed
2689838Drug-induced ototoxicity. Pathogenesis and prevention.Med Toxicol Adverse Drug Exp1989https://conductscience.org/library/papers/2689838PubMed
2369792Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/2369792PubMed
1630874Platinum antitumour agents: a review of (bio)analysis.Pharm Weekbl Sci1992https://conductscience.org/library/papers/1630874PubMed
1394800Effect of coadministration of selenite on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II) given repeatedly to mice.Cancer Chemother Pharmacol1992https://conductscience.org/library/papers/1394800PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2909288

GET https://conductscience.org/api/papers/v1/2909288/authors